Do analysts prefer MGRX or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, MGRX or BMGL?

Basel Medical Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mangoceuticals $460K 21.76 -$20.64M -$1.01 N/A Basel Medical Group $8.90M 0.67 -$9.50M N/A N/A

Do analysts recommend BMGL or AIDX?

20/20 Biolabs has a consensus target price of $5.00, suggesting a potential upside of 1,081.75%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than Basel Medical Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, BMGL or AIDX?

20/20 Biolabs has lower revenue, but higher earnings than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 0.67 -$9.50M N/A N/A 20/20 Biolabs $2.05M 2.64 -$3.74M -$0.54 N/A

Is BMGL or AIDX more profitable?

Company Net Margins Return on Equity Return on Assets Basel Medical Group N/A N/A N/A 20/20 Biolabs N/A N/A N/A

Do analysts recommend GXAI or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, GXAI or BMGL?

Gaxos.ai has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gaxos.ai $1.93M 3.32 -$3.90M -$0.50 N/A Basel Medical Group $8.90M 0.67 -$9.50M N/A N/A

Do analysts rate BIAF or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, BIAF or BMGL?

Basel Medical Group has higher revenue and earnings than bioAffinity Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio bioAffinity Technologies $6.16M 0.76 -$14.91M -$109.45 N/A Basel Medical Group $8.90M 0.67 -$9.50M N/A N/A

Do analysts recommend BMGL or IVF?

INVO Fertility has a consensus target price of $20.00, indicating a potential upside of 2,022.47%. Given INVO Fertility's stronger consensus rating and higher probable upside, analysts clearly believe INVO Fertility is more favorable than Basel Medical Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, BMGL or IVF?

Basel Medical Group has higher revenue and earnings than INVO Fertility. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 0.67 -$9.50M N/A N/A INVO Fertility $6.84M 0.35 -$25.13M -$33.83 N/A

Basel Medical Group (BMGL) Competitors

$3.80 -0.29 (-7.09%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$3.92 +0.12 (+3.24%)

As of 09/24/2026 07:59 PM Eastern

Compare

BMGL vs. MGRX, AIDX, GXAI, BIAF, and IVF

Should you buy Basel Medical Group stock or one of its competitors? Basel Medical Group's main competitors and comparable companies include Mangoceuticals (MGRX), 20/20 Biolabs (AIDX), Gaxos.ai (GXAI), bioAffinity Technologies (BIAF), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Basel Medical Group compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
Basel Medical Group	N/A	N/A	N/A

In the previous week, Mangoceuticals and Mangoceuticals both had 2 articles in the media. Mangoceuticals' average media sentiment score of 0.00 equaled Basel Medical Group'saverage media sentiment score.

Company	Overall Sentiment
Mangoceuticals	Neutral
Basel Medical Group	Neutral

Mangoceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	21.76	-$20.64M	-$1.01	N/A
Basel Medical Group	$8.90M	0.67	-$9.50M	N/A	N/A

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Basel Medical Group beats Mangoceuticals on 5 of the 9 factors compared between the two stocks.

How does Basel Medical Group compare to 20/20 Biolabs?

Basel Medical Group (NASDAQ:BMGL) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

20/20 Biolabs has a consensus target price of $5.00, suggesting a potential upside of 1,081.75%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than Basel Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

20/20 Biolabs has lower revenue, but higher earnings than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	0.67	-$9.50M	N/A	N/A
20/20 Biolabs	$2.05M	2.64	-$3.74M	-$0.54	N/A

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
20/20 Biolabs	N/A	N/A	N/A

In the previous week, 20/20 Biolabs had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for 20/20 Biolabs and 2 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.00 equaled 20/20 Biolabs'average media sentiment score.

Company	Overall Sentiment
Basel Medical Group	Neutral
20/20 Biolabs	Neutral

Summary

20/20 Biolabs beats Basel Medical Group on 6 of the 7 factors compared between the two stocks.

How does Basel Medical Group compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Gaxos.ai has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Gaxos.ai has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$1.93M	3.32	-$3.90M	-$0.50	N/A
Basel Medical Group	$8.90M	0.67	-$9.50M	N/A	N/A

42.6% of Gaxos.ai shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. Basel Medical Group's return on equity of 0.00% beat Gaxos.ai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
Basel Medical Group	N/A	N/A	N/A

In the previous week, Gaxos.ai had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for Gaxos.ai and 2 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.00 beat Gaxos.ai's score of -0.36 indicating that Basel Medical Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Gaxos.ai	Neutral
Basel Medical Group	Neutral

Summary

Gaxos.ai beats Basel Medical Group on 6 of the 11 factors compared between the two stocks.

How does Basel Medical Group compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

In the previous week, bioAffinity Technologies had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for Basel Medical Group. bioAffinity Technologies' average media sentiment score of 0.38 beat Basel Medical Group's score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
bioAffinity Technologies	Neutral
Basel Medical Group	Neutral

Basel Medical Group has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. Basel Medical Group's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-257.30%	-220.52%	-136.76%
Basel Medical Group	N/A	N/A	N/A

Basel Medical Group has higher revenue and earnings than bioAffinity Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16M	0.76	-$14.91M	-$109.45	N/A
Basel Medical Group	$8.90M	0.67	-$9.50M	N/A	N/A

bioAffinity Technologies has a beta of -1.11, meaning that its stock price is 211% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.6% of bioAffinity Technologies shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Basel Medical Group beats bioAffinity Technologies on 6 of the 11 factors compared between the two stocks.

How does Basel Medical Group compare to INVO Fertility?

Basel Medical Group (NASDAQ:BMGL) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

INVO Fertility has a consensus target price of $20.00, indicating a potential upside of 2,022.47%. Given INVO Fertility's stronger consensus rating and higher probable upside, analysts clearly believe INVO Fertility is more favorable than Basel Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Basel Medical Group has higher revenue and earnings than INVO Fertility.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	0.67	-$9.50M	N/A	N/A
INVO Fertility	$6.84M	0.35	-$25.13M	-$33.83	N/A

In the previous week, INVO Fertility had 2 more articles in the media than Basel Medical Group. MarketBeat recorded 4 mentions for INVO Fertility and 2 mentions for Basel Medical Group. INVO Fertility's average media sentiment score of 1.02 beat Basel Medical Group's score of 0.00 indicating that INVO Fertility is being referred to more favorably in the news media.

Company	Overall Sentiment
Basel Medical Group	Neutral
INVO Fertility	Positive

Basel Medical Group has a net margin of 0.00% compared to INVO Fertility's net margin of -116.29%. Basel Medical Group's return on equity of 0.00% beat INVO Fertility's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
INVO Fertility	-116.29%	-85.54%	-31.05%

Basel Medical Group has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, INVO Fertility has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

12.0% of INVO Fertility shares are owned by institutional investors. 0.4% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

INVO Fertility beats Basel Medical Group on 8 of the 14 factors compared between the two stocks.

Get Basel Medical Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMGL vs. The Competition

Export

Metric	Basel Medical Group	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.63M	$9.75B	$7.32B	$13.29B
Dividend Yield	N/A	2.59%	2.52%	12.57%
P/E Ratio	N/A	34.16	274.41	25.76
Price / Sales	0.67	4.96	688.46	106.29
Price / Cash	N/A	122.11	77.80	52.76
Price / Book	1.56	5.19	10.52	6.34
Net Income	-$9.50M	$315.70M	$3.49B	$360.00M
7 Day Performance	-17.57%	-1.37%	-0.94%	-0.16%
1 Month Performance	-18.77%	-1.40%	-4.24%	-4.08%
1 Year Performance	-82.21%	13.92%	16.38%	5.97%

Basel Medical Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMGL Basel Medical Group	0.0771 of 5 stars	$3.80 -7.1%	N/A	-82.5%	$6.63M	$8.90M	N/A	70	Short Interest Increase
MGRX Mangoceuticals	0.8241 of 5 stars	$0.40 +4.6%	N/A	-80.9%	$8.69M	$460K	N/A	3
AIDX 20/20 Biolabs	2.0642 of 5 stars	$0.56 +3.6%	$5.00 +792.9%	N/A	$7.15M	$2.05M	N/A	14	Short Interest Decrease
GXAI Gaxos.ai	0.5223 of 5 stars	$0.68 -8.5%	N/A	-67.9%	$4.85M	$1.93M	N/A	3
BIAF bioAffinity Technologies	0.4397 of 5 stars	$7.95 -15.3%	N/A	-87.8%	$4.78M	$6.16M	N/A	10	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMGL) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Basel Medical Group (BMGL) Competitors

BMGL vs. MGRX, AIDX, GXAI, BIAF, and IVF

How does Basel Medical Group compare to Mangoceuticals?

Summary

How does Basel Medical Group compare to 20/20 Biolabs?

Summary

How does Basel Medical Group compare to Gaxos.ai?

Summary

How does Basel Medical Group compare to bioAffinity Technologies?

Summary

How does Basel Medical Group compare to INVO Fertility?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMGL vs. The Competition

Basel Medical Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Basel Medical Group (BMGL) Competitors

BMGL vs. MGRX, AIDX, GXAI, BIAF, and IVF

How does Basel Medical Group compare to Mangoceuticals?

Do analysts prefer MGRX or BMGL?

Is MGRX or BMGL more profitable?

Does the media favor MGRX or BMGL?

Which has more volatility and risk, MGRX or BMGL?

Which has higher valuation & earnings, MGRX or BMGL?

Do institutionals & insiders hold more shares of MGRX or BMGL?

Summary

How does Basel Medical Group compare to 20/20 Biolabs?

Do analysts recommend BMGL or AIDX?

Which has stronger earnings & valuation, BMGL or AIDX?

Is BMGL or AIDX more profitable?

Does the media prefer BMGL or AIDX?

Summary

How does Basel Medical Group compare to Gaxos.ai?

Which has more risk & volatility, GXAI or BMGL?

Which has preferable valuation & earnings, GXAI or BMGL?

Do insiders and institutionals hold more shares of GXAI or BMGL?

Do analysts recommend GXAI or BMGL?

Is GXAI or BMGL more profitable?

Does the media prefer GXAI or BMGL?

Summary

How does Basel Medical Group compare to bioAffinity Technologies?

Does the media favor BIAF or BMGL?

Is BIAF or BMGL more profitable?

Which has better valuation & earnings, BIAF or BMGL?

Which has more volatility and risk, BIAF or BMGL?

Do analysts rate BIAF or BMGL?

Do institutionals & insiders believe in BIAF or BMGL?

Summary

How does Basel Medical Group compare to INVO Fertility?

Do analysts recommend BMGL or IVF?

Which has preferable earnings & valuation, BMGL or IVF?

Does the media refer more to BMGL or IVF?

Is BMGL or IVF more profitable?

Which has more risk and volatility, BMGL or IVF?

Do institutionals and insiders believe in BMGL or IVF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMGL vs. The Competition

Basel Medical Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools